Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre studyJames F. Howard, Daniel Ambrosio, Kimiaki Utsugisawa et al.|The Lancet Neurology|2017Cited by 820
Th1 Response and Systemic Treg Deficiency in Inclusion Body MyositisYves Allenbach, Olivier Benvéniste, Nicolas Prevel et al.|PLoS ONE|2014Cited by 84